Business Context and Reporting Period
Unicycive Therapeutics, Inc. (UNCY) filed a Current Report on Form 8-K on June 17, 2025, regarding a corporate action approved by stockholders at the annual meeting on June 9, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Los Altos, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a capital structure modification.
Material Changes
- Reverse Stock Split: The Board executed a 1-for-10 reverse stock split of the Company's common stock.
- Effective Date: The split became effective at 4:01 p.m. Eastern Time on June 18, 2025.
- Trading Resumption: Common stock began trading on a split-adjusted basis on June 20, 2025, under the existing symbol "UNCY" with a new CUSIP number (90466Y202).
- Share Count Reduction: Issued and outstanding shares decreased from approximately 126,409,281 to approximately 12,768,239.
- Fractional Shares: No fractional shares were issued; fractional interests were rounded up to the next whole share.
- Adjustments: Proportionate adjustments were made to exercise prices and share counts for outstanding stock options, warrants, and the conversion price of Series A-2 Prime Preferred Stock.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard implications of a reverse stock split. The Company noted that the split will not change any stockholder's percentage ownership interest or proportionate voting power, except for immaterial changes resulting from fractional share rounding.
Investor Verification Checklist
- Verify the new CUSIP number (90466Y202) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Review the impact of the 1-for-10 ratio on the exercise price and share count of any held stock options or warrants.
- Check the updated share count of approximately 12.77 million outstanding shares in subsequent filings.